These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 15655705)

  • 1. Circulation and degradation of GIP and GLP-1.
    Deacon CF
    Horm Metab Res; 2004; 36(11-12):761-5. PubMed ID: 15655705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What do we know about the secretion and degradation of incretin hormones?
    Deacon CF
    Regul Pept; 2005 Jun; 128(2):117-24. PubMed ID: 15780431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD; Gault VA; O'Harte FP; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP.
    Mentlein R
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):443-52. PubMed ID: 19748062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
    Diamant M; Bunck MC; Heine RJ
    Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
    Meier JJ; Nauck MA; Kranz D; Holst JJ; Deacon CF; Gaeckler D; Schmidt WE; Gallwitz B
    Diabetes; 2004 Mar; 53(3):654-62. PubMed ID: 14988249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.
    Deacon CF; Wamberg S; Bie P; Hughes TE; Holst JJ
    J Endocrinol; 2002 Feb; 172(2):355-62. PubMed ID: 11834453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous determination of incretin hormones and their truncated forms from human plasma by immunoprecipitation and liquid chromatography-mass spectrometry.
    Wolf R; Hoffmann T; Rosche F; Demuth HU
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Apr; 803(1):91-9. PubMed ID: 15026002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
    Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
    Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.
    Mentlein R; Gallwitz B; Schmidt WE
    Eur J Biochem; 1993 Jun; 214(3):829-35. PubMed ID: 8100523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and intestinal concentrations of GIP and GLP-1 (7-36) amide during suckling and after weaning in pigs.
    Knapper JM; Morgan LM; Fletcher JM; Marks V
    Horm Metab Res; 1995 Nov; 27(11):485-90. PubMed ID: 8770623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin and islet hormonal responses to fat and protein ingestion in healthy men.
    Carr RD; Larsen MO; Winzell MS; Jelic K; Lindgren O; Deacon CF; Ahrén B
    Am J Physiol Endocrinol Metab; 2008 Oct; 295(4):E779-84. PubMed ID: 18612044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?
    McIntosh CH; Demuth HU; Pospisilik JA; Pederson R
    Regul Pept; 2005 Jun; 128(2):159-65. PubMed ID: 15780435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
    Kieffer TJ; McIntosh CH; Pederson RA
    Endocrinology; 1995 Aug; 136(8):3585-96. PubMed ID: 7628397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N; McClean PL; Flatt PR
    J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.
    Lindsay JR; Duffy NA; McKillop AM; Ardill J; O'Harte FP; Flatt PR; Bell PM
    Diabet Med; 2005 May; 22(5):654-7. PubMed ID: 15842525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the physiology of GIP and GLP-1.
    Holst JJ
    Horm Metab Res; 2004; 36(11-12):747-54. PubMed ID: 15655703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy.
    Andersen O; Haugaard SB; Holst JJ; Deacon CF; Iversen J; Andersen UB; Nielsen JO; Madsbad S
    HIV Med; 2005 Mar; 6(2):91-8. PubMed ID: 15807714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
    Langley AK; Suffoletta TJ; Jennings HR
    Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
    Pei Z
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.